全文获取类型
收费全文 | 1608篇 |
免费 | 103篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 73篇 |
妇产科学 | 15篇 |
基础医学 | 144篇 |
口腔科学 | 52篇 |
临床医学 | 153篇 |
内科学 | 682篇 |
皮肤病学 | 24篇 |
神经病学 | 48篇 |
特种医学 | 265篇 |
外科学 | 82篇 |
综合类 | 33篇 |
预防医学 | 49篇 |
眼科学 | 4篇 |
药学 | 61篇 |
中国医学 | 1篇 |
肿瘤学 | 51篇 |
出版年
2021年 | 27篇 |
2019年 | 13篇 |
2018年 | 35篇 |
2017年 | 14篇 |
2016年 | 10篇 |
2015年 | 19篇 |
2014年 | 36篇 |
2013年 | 36篇 |
2012年 | 43篇 |
2011年 | 43篇 |
2010年 | 61篇 |
2009年 | 53篇 |
2008年 | 44篇 |
2007年 | 70篇 |
2006年 | 51篇 |
2005年 | 57篇 |
2004年 | 38篇 |
2003年 | 41篇 |
2002年 | 40篇 |
2001年 | 32篇 |
2000年 | 32篇 |
1999年 | 32篇 |
1998年 | 64篇 |
1997年 | 75篇 |
1996年 | 80篇 |
1995年 | 52篇 |
1994年 | 41篇 |
1993年 | 46篇 |
1992年 | 31篇 |
1991年 | 21篇 |
1990年 | 31篇 |
1989年 | 52篇 |
1988年 | 49篇 |
1987年 | 46篇 |
1986年 | 50篇 |
1985年 | 42篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 19篇 |
1981年 | 19篇 |
1980年 | 18篇 |
1979年 | 18篇 |
1978年 | 16篇 |
1977年 | 19篇 |
1976年 | 14篇 |
1975年 | 19篇 |
1974年 | 9篇 |
1973年 | 9篇 |
1972年 | 7篇 |
1971年 | 7篇 |
排序方式: 共有1740条查询结果,搜索用时 15 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
3.
4.
Sonoelasticity imaging of prostate cancer: in vitro results 总被引:2,自引:0,他引:2
5.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献
6.
7.
8.
9.
10.